Editorial | What now, DOH?

The controversy on the Dengvaxia vaccine has started to subside after former and current officials were sued as the result of the investigation on the issue.

Former and current top government officials were sued after it was found out that the vaccine, initially designed to prevent dengue, could even cause a much greater risk.

However, in the latest story that came out last weekend, the manufacturer, Sanofi Pasteur, claimed that a new study revealed that the vaccine, instead of preventing or curing dengue, has exposed those who were vaccinated to severe risk.

In a statement, the company said: “In this supplementary analysis, we found an increased incidence of severe disease in vaccinated people without a prior infection compared to unvaccinated people without a prior infection.”

However, as if to cushion the impact of the previous findings, the company claimed that the new study also showed that the vaccine has a high potential to prevent dengue for those who were previously afflicted with it.

However, despite these new developments, one issue that has continued to linger on is the question of what the next step of the government, particularly the Department of Health (DOH), needs to take to prevent the spread of the disease.

This is aside from the fact that so much has been lost to the implementation of the Dengvaxia program as well as the failure of the previous administration to institute due diligence in implementing it.

The DOH must design a new program not only to help prevent the diseases, but also to make sure that everything is according to the goal, and not according to the personal interest of those in power.

Posted in Opinion